Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.
Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Christophe Le Tourneau(Institut Curie), Barbara Burtness(Yale University), Ramona F. Swaby(Merck & Co., Inc., Rahway, NJ, USA (United States)), Myung‐Ju Ahn(Sungkyunkwan University), Ranee Mehra(University of Maryland, Baltimore), Lisa Licitra(University of Milan), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Jean‐Pascal Machiels(Cliniques Universitaires Saint-Luc), José Dinis(Instituto Português de Oncologia Francisco Gentil), Ainara Soria(Hospital Universitario Ramón y Cajal), Jianxin Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ezra E.W. Cohen(Moores Cancer Center), Jonathan D. Cheng(Princeton University), Nicolas Mach(University of Geneva)
Cited by 4
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k